Netupitant Market

Netupitant Market Size, Share & Industry Analysis, By Application (Chemotherapy-Induced Nausea and Vomiting, Postoperative Nausea and Vomiting, Radiotherapy-Induced Nausea), By Source (In-house API Manufacturing Units, Contract Manufacturing Organizations, Third-Party Bulk API Suppliers), By End-User Industry (Pharmaceutical Manufacturers, Oncology Clinics, Hospitals and Healthcare Institutions, Research and Development Laboratories), and Forecast, 2025–2035

The Netupitant market is projected to grow at a CAGR of 4.1% during the forecast period of 2025–2035. This growth is primarily driven by the increasing prevalence of chemotherapy-induced nausea and vomiting (CINV), as well as postoperative and radiotherapy-induced nausea. Netupitant’s efficacy as a neurokinin-1 (NK1) receptor antagonist, especially in combination therapies, supports its rising adoption in oncology and supportive care.

Regionally, North America is expected to lead the Netupitant API market, owing to advanced healthcare infrastructure, high awareness of antiemetic therapies, and significant investments in oncology research. Europe follows closely, supported by strong regulatory frameworks and increasing adoption of combination antiemetic therapies. The Asia-Pacific region is anticipated to witness the fastest growth, driven by improving healthcare access, rising cancer prevalence, and expanding pharmaceutical manufacturing in countries like China and India.

The market report benefits from continuous advancements in manufacturing technologies, such as enzymatic asymmetric oxidation and batch chemical synthesis, which enhance Netupitant’s efficacy and consistency. Rising demand from pharmaceutical companies, hospitals, and oncology clinics for both prescription and combination formulations is also boosting market growth. However, challenges including regulatory constraints, pricing pressures, and competition from alternative antiemetic agents may impact growth in certain regions.

Seeking Comprehensive Intelligence on Different markets? Get in Touch with our Experts

Report Scope & Segmentation

  1. Introduction
  • Overview of Netupitant
  • Key Applications & Industry Use Cases
  • Market Scope & Study Objectives
  1. Market Overview
  • Global Market Size & Growth Trends (Historical & Forecast)
  • Market Value & Revenue Analysis
  • Demand-Supply Dynamics
  1. Segmental Outlook
  • By Application
    • Chemotherapy-Induced Nausea and Vomiting (CINV)
    • Postoperative Nausea and Vomiting (PONV)
    • Radiotherapy-Induced Nausea
  • By Source
    • In-house API Manufacturing Units
    • Contract Manufacturing Organizations (CMOs)
    • Third-Party Bulk API Suppliers
  • Key End-User Industry
    • Pharmaceutical Manufacturers
    • Oncology Clinics
    • Hospitals and Healthcare Institutions
    • Research and Development Laboratories

 

  1. Price Analysis
  • Current Price Trends (Per kg & Per Ton)
  • Price Fluctuation Factors (Raw Material Costs, Production, Trade Tariffs)
  • Regional Price Comparison (North America, Europe, Asia-Pacific, and Other)
  1. Production & Supply Volume
  • Global Production Capacity & Key Manufacturers
  • Production Process & Technological Developments
  • Raw Material Analysis
  1. Trade Analysis (Import & Export)
  • Major Exporting & Importing Countries
  • Trade Volume & Value Statistics
  • Impact of Trade Regulations & Policies
  1. Regional Analysis
  • North America (US and Canada)
  • Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, Taiwan, India, and Rest of Asia-Pacific)
  • Rest of the World (Latin America and Middle East and Africa)
  1. Competitive Landscape
  • Top Global Manufacturers & Market Share
  • Company Profiles & Key Developments
  • Mergers, Acquisitions & Investments
  1. Regulatory & Compliance Factors
  • FDA, REACH, and Other Regulatory Frameworks
  • Environmental & Safety Considerations
  • Emerging Policies Impacting Market Growth
  1. Conclusion & Strategic Recommendations
  • Key Takeaways for Stakeholders
  • Market Entry Strategies

 

What is Netupitant?
Netupitant is a selective neurokinin-1 (NK1) receptor antagonist used primarily in combination with palonosetron to prevent chemotherapy-induced nausea and vomiting (CINV). It works by blocking the action of substance P, a key chemical involved in triggering nausea.
What is the market size for Netupitant?
The Netupitant market is projected to grow at a CAGR of 4.1% during the forecast period 2025–2035. The steady growth reflects rising global cancer cases and the growing need for effective antiemetic therapies.
What are the drivers for the Netupitant market?
Key drivers include increasing cancer incidence, greater adoption of combination therapies (like Netupitant-Palonosetron), and advancements in API manufacturing technologies. Growing use in supportive cancer care and hospital-based oncology regimens also fuels demand.
Who are the key players operating in the Netupitant market?
Major players include Hetero Labs, MSN Laboratories, Dr. Reddy’s Laboratories, Cipla, Teva Pharmaceuticals, Glenmark Pharmaceuticals, and Jubilant Biosys.
Which region is expected to exhibit the fastest growth in the Netupitant market?
The Asia-Pacific region is expected to show the fastest growth due to increasing access to cancer care, rising healthcare expenditure, and large-scale pharmaceutical production in countries like India and China.
$1800/- Single User License
$3600/- Multi User License

How can we help you?

Reach out to discuss how our team can help your business achieve real results.